Immunotherapies for Hodgkin's lymphoma.
Multiple immune evasion strategies characterize the pathobiology of Hodgkin's lymphoma. These must be considered when developing and testing immunotherapeutic approaches for this disease. The clinical experience with adoptive immunotherapy of Epstein-Barr virus positive tumors, and with monoclonal antibodies directed against CD30, CD20, and other antigens, is herein reviewed.
Kasamon
Yvette L
YL
Division of Hematologic Malignancies, Johns Hopkins Medical Institutions, Baltimore, MD, USA. ykasamo1@jhmi.edu
Ambinder
Richard F
RF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use; D004854:Herpesvirus 4, Human / Q000276:immunology; D006689:Hodgkin Disease / Q000276:immunology / Q000628:therapy* / Q000821:virology; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D016219:Immunotherapy, Adoptive; D017730:Ki-1 Antigen / Q000276:immunology; D018714:Radiotherapy, Adjuvant; D000069283:Rituximab; D016896:Treatment Outcome; D019139:Tumor Escape
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000069283:Rituximab